AZN : Analysis & Opinions

  1. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  2. The United Kingdom Is Ripe For Stock Pickers

    December 6, 2013
    With the situation in Europe finally moving ahead, investors may want to focus on the United Kingdom. Stocks within the nation ...
  3. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  4. Yet Another Failure Has Rigel Pharmaceuticals Almost Back To ...

    August 26, 2013
    Rigel sees yet another clinical failure from its pipeline.
  5. Does Amgen Deserve To Be Part Of The Biotech Bull Run?

    July 31, 2013
    Amgen is beating growth targets today, but fears about generics and a dull pipeline concern investors.
  6. Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook

    July 30, 2013
    Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook
  7. Pipeline Setback for Roche - Analyst Blog

    July 12, 2013
    Roche recently suffered a setback when it announced the termination of its phase III trial, AleCardio, on pipeline candidate ...
  8. Omthera Seeks FDA Approval for Epanova - Analyst Blog

    July 10, 2013
    Omthera Pharma submitted a new drug application (NDA) for its cholesterol management candidate, Epanova
  9. Amarin Offers American Depositary Shares - Analyst Blog

    July 9, 2013
    Amarin Corporation announced its offer to sell 21.7 million American Depositary Shares
  10. Impax Challenges Toviaz Patent - Analyst Blog

    July 5, 2013
    Impax Laboratories announced that it is looking to get its generic version of Toviaz tablets approved in the US.
  11. Sanofi's Lyxumia Gets Japanese Nod - Analyst Blog

    July 2, 2013
    Sanofi announced that Lyxumia has been cleared by Japan's Ministry of Health, Labour and Welfare
  12. Encouraging Data on Sanofi's Lixisenatide - Analyst Blog

    June 25, 2013
    Sanofi presented positive data on its type II diabetes drug, lixisenatide
  13. Positive Phase III Data on Sanofi's U300 - Analyst Blog

    June 24, 2013
    Sanofi announced encouraging data from two phase III studies evaluating U300.
  14. ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...

    June 24, 2013
    Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
  15. AstraZeneca and NGM Collaborate - Analyst Blog

    June 18, 2013
    AstraZeneca entered into an agreement with NGM Biopharmaceuticals, Inc. to develop candidates for type II diabetes and obesity.
  16. Sanofi's Fluzone Quadrivalent Gets FDA Nod - Analyst Blog

    June 13, 2013
    Sanofi announced that the FDA has cleared its quadrivalent formulation of Fluzone
  17. Dynavax Down on Heplisav Delay - Analyst Blog

    June 11, 2013
    Dynavax recently suffered a setback when the US Food and Drug Administration (FDA) asked for additional safety data on its ...
  18. CHMP Positive on Sanofi's Lantus - Analyst Blog

    June 11, 2013
    The Committee for Medicinal Products for Human Use issued a positive opinion related to Lantus
  19. AstraZeneca Resolves Nexium Issue - Analyst Blog

    June 10, 2013
    AstraZeneca entered into an agreement with Hanmi Pharmaceutical to resolve patent issues related to Nexium
  20. Generics Hurt AZN Results - Analyst Blog

    February 4, 2013
    AstraZeneca's (AZN) fourth-quarter 2012 core earnings of $1.56 per American Depositary Share (ADS) beat the Zacks Consensus ...
  21. Earnings Preview: Amgen - Analyst Blog

    January 22, 2013
    Amgen (AMGN) is scheduled to report its fourth quarter 2012 results on Jan 23, 2013 after the closing bell. Last quarter, ...
  22. Cubist: Another Solid Quarter? - Analyst Blog

    January 22, 2013
    We expect Cubist Pharmaceuticals Inc. (CBST) to beat expectations when it releases its fourth-quarter 2012 results on Jan ...
  23. Management Expands at AstraZeneca - Analyst Blog

    January 17, 2013
    AstraZeneca (AZN) recently announced that the company has created seven positions in the senior executive team. At the same ...
  24. Data on Novartis' Afinitor - Analyst Blog

    January 14, 2013
    As per recent data published in The Lancet, Novartis' (NVS) cancer drug, Afinitor (everolimus), helped reduce the tumor size ...
  25. Lilly to Go Solo with LY2605541 - Analyst Blog

    January 11, 2013
    Eli Lilly and Company (LLY) recently announced that it will be developing diabetes candidate, LY2605541, on its own. The ...
  26. Optimer's Dificid Sales Look Good - Analyst Blog

    January 9, 2013
    Optimer Pharmaceuticals Inc. (OPTR) recently announced its preliminary sales for the fourth quarter and full year 2012. ...
  27. Pipeline Update from Alnylam - Analyst Blog

    January 8, 2013
    Alnylam Pharmaceuticals Inc (ALNY) recently announced its goal for the next two years (2013 and 2014) regarding its key "Alnylam ...
  28. Charles River Acquires Vital River - Analyst Blog

    January 8, 2013
    Charles River Laboratories International, Inc. (CRL) recently completed its previously announced acquisition of 75% ownership ...
  29. Neutral on Sanofi - Analyst Blog

    December 31, 2012
    We are maintaining our Neutral recommendation on Sanofi (SNY). The stock carries a Zacks #3 Rank (Hold) in the short run. ...
  30. Raptor Drug FDA Action Date Delayed - Analyst Blog

    December 28, 2012
    Raptor Pharmaceutical Corp. (RPTP) recently announced that the US Food and Drug Administration (FDA) has extended the review ...
  31. Acorda Completes Acquisition of Neuronex - Analyst Blog

    December 27, 2012
    Acorda Therapeutics, Inc. (ACOR) recently completed the acquisition of privately-held Neuronex, Inc. As per the agreement ...
  32. Oncothyreon/Merck KGaA Drug Fails - Analyst Blog

    December 27, 2012
    Oncothyreon Inc. (ONTY) and its partner, Merck KGaA (MKGAY) recently presented disappointing data from a phase III trial ...
  33. Glaxo's Influenza Vaccine Approved - Analyst Blog

    December 24, 2012
    GlaxoSmithKline (GSK) recently announced that it has received US Food and Drug Administration (FDA) approval for its influenza ...
  34. Myriad Teams Up with Sanofi - Analyst Blog

    December 11, 2012
    Myriad RBM, a wholly-owned subsidiary of molecular diagnostic company Myriad Genetics Inc. (MYGN), has recently collaborated ...
  35. FDA Updates AZN's Faslodex Label - Analyst Blog

    December 6, 2012
    AstraZeneca (AZN) recently announced that it has reached an agreement with the US Food and Drug Administration (FDA) regarding ...
  36. Revenues Decline at Alnylam - Analyst Blog

    November 7, 2012
    Alnylam Pharmaceuticals Inc.'s (ALNY) third quarter 2012 net loss of 38 cents per share was wider than the year-ago loss ...
  37. Pfizer Misses on Revs, Narrows View - Analyst Blog

    November 1, 2012
    Pfizer Inc. (PFE) posted third quarter earnings of 53 cents per share, a penny above the Zacks Consensus Estimate but 12% ...
  38. Earnings Preview: Merck & Co. - Analyst Blog

    October 25, 2012
    Merck & Co. Inc. (MRK) is set to announce its second quarter 2012 results on July 27, 2012, before the opening bell. The ...
  39. Generic Plavix Hurts Bristol-Myers - Analyst Blog

    October 24, 2012
    Bristol-Myers Squibb Company's (BMY) second quarter 2012 earnings (excluding special items) of 48 cents per share fell short ...
  40. Isis Pharma Owns 18% of Regulus - Analyst Blog

    October 12, 2012
    Isis Pharmaceuticals, Inc. (ISIS) recently announced that it has invested $3 million in biopharma company Regulus Therapeutics ...
  41. Alnylam-ISIS Venture Prices IPO - Analyst Blog

    October 5, 2012
    Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, Inc. (ISIS), recently announced ...
  42. Phase III Data on Novartis' RLX030 - Analyst Blog

    September 25, 2012
    Switzerland-based pharmaceutical company, Novartis AG (NVS) recently announced phase III data on its pipeline candidate, ...
  43. CHMP Positive on Novartis' Votubia - Analyst Blog

    September 24, 2012
    Switzerland-based pharmaceutical company, Novartis AG (NVS) recently announced that the Committee for Medicinal Products ...
  44. Dr. Reddy's Launches Generic Amoxil - Analyst Blog

    September 21, 2012
    Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of GlaxoSmithKline's (GSK) Amoxil (amoxicillin) ...
  45. Invest Like a Machine! - Investment Ideas

    September 21, 2012
    Last week, the Chicago Quantitative Alliance (CQA) held its annual fall conference. As a member, I was able to attend this ...
  46. Dr. Reddy's Launches Generic Toprol - Analyst Blog

    September 12, 2012
    Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of AstraZeneca's (AZN) hypertension drug ...
  47. Still Neutral on Bristol-Myers - Analyst Blog

    September 6, 2012
    We are maintaining our Neutral recommendation on Bristol-Myers Squibb Company (BMY) with a target price of $35.00. The stock ...
  48. The Week In Healthcare

    August 31, 2012
    Although this has been a solid year for med-tech, some sub-sectors are starting to lag a bit during this late summer rally.
  49. DENTSPLY Remains Neutral - Analyst Blog

    August 27, 2012
    We reiterate our Neutral recommendation on DENTSPLY International Inc. (XRAY). Its second quarter 2012 adjusted earnings ...
  50. Alnylam/Isis's Regulus to Go Public - Analyst Blog

    August 22, 2012
    Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, Inc. (ISIS), recently announced ...
  51. Generic Xopenex Launch by Watson - Analyst Blog

    August 21, 2012
    Watson Pharmaceuticals Inc. (WPI) recently announced the launch of an authorized generic version of Sunovion Pharmaceuticals ...
  52. Biogen Inks Deal with Regulus - Analyst Blog

    August 16, 2012
    Regulus Therapeutics Inc. and Biogen Idec (BIIB) recently entered into a deal to identify microRNAs (micro-RiboNucleic Acids) ...
  53. Par Pharma Beats Estimates - Analyst Blog

    August 6, 2012
    Par Pharmaceutical Companies Inc. (PRX) posted second quarter 2012 adjusted earnings of $1.62 per share, well above the Zacks ...
  54. Angiomax Drives MDCO's Results - Analyst Blog

    July 26, 2012
    The Medicines Company (MDCO) reported second quarter earnings of 25 cents per share. Second quarter earnings were well above ...
  55. Merck KGaA's Erbitux Disappoints - Analyst Blog

    July 10, 2012
    Merck KGaA (MKGAF) recently announced that Erbitux failed to achieve its primary endpoint in the phase III EXPAND trial, ...
  56. GolinHarris Acquires Virgo Health - Analyst Blog

    July 6, 2012
    GolinHarris, a division of Interpublic Group (IPG) intends to acquire Virgo Heath, an independent UK-based Healthcare Communications ...
  57. MDCO's Cangrelor Enrollment by 4Q - Analyst Blog

    July 3, 2012
    The Medicines Company (MDCO) recently announced that patient enrollment for its pivotal phase III CHAMPION PHOENIX trial ...
  58. Bristol-Myers to Buy Amylin - Analyst Blog

    July 2, 2012
    In a bid to diversify its business to combat the generic threat and bolster its position in the lucrative diabetes market, ...
  59. AstraZeneca Buys Ardea Biosciences - Analyst Blog

    June 21, 2012
    AstraZeneca plc (AZN) recently announced that it has completed the acquisition of Ardea Biosciences, Inc. for approximately ...
  60. Bristol-Myers Shares Positive Data - Analyst Blog

    June 11, 2012
    Recently, Bristol-Myers Squibb (BMY) and partner AstraZeneca (AZN) presented encouraging data from a phase III study (n=447) ...
  61. The Costs Of Being Obese

    May 2, 2012
    Numbers released by the Mayo Clinic suggest obesity costs more than smoking.
  62. Value At Abbott Labs Balances A Lot Of Growth Optimism

    February 14, 2012
    Growth expectations may be too high for Abbott.
  63. Big Buys In Share Buybacks

    January 27, 2012
    Record corporate profits and super low interest rates are resulting in a shrinking market environment and a rise in share ...
  64. The Salix Story Keeps Improving

    January 18, 2012
    Salix is a great candidate for growth investors.
  65. The War Against Alzheimer's Requires Thinking Small

    January 2, 2012
    A meaningful treatment for Alzheimer's is no longer out of reach. Find out which companies are in the race to find a cure.
  66. 10 Picks from a Master Contrarian

    December 21, 2011
    Generally speaking, it's not the greatest compliment to be called contrary, but in the case of investors, some of the best, ...
  67. Big Values In Big Pharma

    November 1, 2011
    The major pharmaceutical firms now represent value. These companies could represent a great income play.
  68. The Contrarian Play In Europe

    October 26, 2011
    Nothing could be bolder than adding European stocks to a portfolio. Europe offers a fertile ground for contrarian investors.
  69. The Overlooked Dental Health Sector

    August 25, 2011
    While health care remains a great long-term portfolio position, many investors ignore the dental sub-sector. However, benefiting ...
  70. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  71. 5-Star Healthcare Dividend Stocks

    April 28, 2011
    Healthcare is an increasingly worthwhile destination for dividend shoppers.
  72. Lilly Will Pay Investors For Patience

    April 20, 2011
    Lilly isn't dynamic, but the value is there.
  73. Amarin's Magic Pill

    April 19, 2011
    Strong clinical data sends Amarin's stock soaring.
  74. Healthy Dividend-Growth Ideas In Healthcare

    March 16, 2011
    Healthcare is an increasingly worthwhile destination for dividend shoppers.
  75. Glaxo And Human Genome Find Rare FDA Success

    March 10, 2011
    With an increasingly scarce FDA approval in hand, HGSI and GSK look to build a blockbuster drug.
  76. Salix Proves There Is Still Growth In Pharma

    March 3, 2011
    Salix has taken another blow from the FDA, but seems too cheap given its prospects.
  77. Can New Leadership Rejuvenate Big Pharma?

    December 8, 2010
    Will another new drug company CEO make a difference in a stagnating industry?
  78. Novartis On The Right Track

    July 19, 2010
    With recent sales increases and a solid pipeline, Novartis deserves a spot on the watchlist of anybody looking at Big Pharma.
  79. The Future of Stem Cells

    June 15, 2010
    Stem cells get a lot of attention, but maybe not in the one area where they could prove most effective.
  80. FDA Makes InterMune Sick

    May 10, 2010
    Should investors hang on despite a devastating FDA decision?
  81. Relief With Bristol-Myers Squibb

    May 6, 2010
    BMY's strong reaction after first-quarter earnings seems more like relief, as the company still has many challenges to surmount.
  82. GlaxoSmithKline On Simmer

    April 30, 2010
    Glaxo's earnings look powerful, but is this really a top idea in the pharma sector?
  83. McKesson Riding High On H1N1

    October 29, 2009
    Investors should keep a close watch on drug distribution firm McKesson's stock.
  84. Buying England By The Pound

    October 28, 2009
    In the forex market, it's time to take advantage of the the cheap pound.
  85. The 5 Most Important Drugs In America

    July 28, 2009
    A look at the top-selling drugs finds that a few that make more of a difference to the company's bottom line than others.
  86. Swine Flu Vaccine: Quantity Over Quality

    July 20, 2009
    The swine flu vaccine race appears to have multiple winners.
  87. Four Breakout Biotech Stocks

    June 12, 2009
    These four biotech stocks are currently on the upswing.
  88. Five Dividend Darlings

    April 29, 2009
    Dividend-paying stocks definitely have advantages. If your portfolio could use some downside protection, check out our list.
  89. Big Pharma's Buying Spree

    April 24, 2009
    A look at recent merger and acquisition activity in the pharmaceutical sector and possible opportunities if the trend continues.
  90. Alcon Takes A Poke In The Eye

    October 28, 2008
    Despite investor worries over Alcon's growth, the eye care company is a proven winner.
  91. Don't Let A Sciele Happen To You

    September 4, 2008
    A great idea is worth nothing if you never pull the trigger.
  92. Five Stocks That Are Defying Market Conditions

    August 4, 2008
    Not all companies are missing earnings - some are even beating earnings and raising guidance.
  93. Leap Of Faith Healing (MEDX, PDLI, AMLN)

    August 8, 2007
    Make the leap with three pharmaceutical companies who require investor courage but could provide a healthy return.
  94. Serving A Critical Need (BIIB, GENZ, MEDI)

    May 3, 2007
    These three drug companies seem to have a healthy upside, but there's always uncertainty in the biotech industry.
  95. Time To Sell Merck? (MRK)

    November 1, 2006
    Merck shareholders cannot afford to shrug off the drug giant’s risks.
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center